SAS Output

21-AUG-2019 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 56 28 15 9 3 1 0 02/06/2017 104 44
            28 15 9 3 1 0      
 
  S1607-MELAN, Adv, T-VEC, MK-3475 1 Y 1 T-VEC + MK-3475(pembrolizumab) 64 21 19 10 4 1 0 06/05/2018 68 27
            21 19 10 4 1 0      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 15 7 7 5 1 0 10/23/2017 231 95
        2 Nivolumab + Ipilimumab   42 28 20 13 7 0      
            57 35 27 18 8 0      
 
  S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab 1 Y 1 Adjuvant Arm 556 23 23 22 16 5 1 02/15/2019 285 114
        2 Neoadjuvant Pembrolizumab   21 21 21 15 4 2      
            44 44 43 31 9 3      
 
    2 Y 3 Surgery 556 29 29 28 25 10 3 02/15/2019    
            29 29 28 25 10 3      
 
    3 Y 4 Post-Surgery Pembro 556 11 11 11 10 6 1 02/15/2019    
            11 11 11 10 6 1      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   41 14 9 4 0 0 11/03/2015 289 122
            41 14 9 4 0 0      
 
    2 E Total Registrations   14 4 2 0 0 0 11/03/2015    
            14 4 2 0 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 0 0 0 0 0 03/25/2016 220 93
            36 0 0 0 0 0      
 
No EA6174-Merkel, Adjuvant Pembrolizumab vs Observation 1 E Total Registrations   1 1 1 0 0 0 05/01/2019 66 32
            1 1 1 0 0 0